Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1561-1580 of 1,743 trials

ADPKD Treatment: Metformin vs. Tolvaptan

We are studying whether Metformin can effectively slow kidney function decline in adults with Autosomal Dominant Polycystic Kidney Disease compared to Tolvaptan. The trial also examines the safety and impact on kidney size and symptoms.

Autosomal Dominant Polycystic Kidney Disease>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Hydrocortisone Treatment in Pancreatoduodenectomy Surgery

We are studying whether hydrocortisone infusions can help reduce complications after pancreatoduodenectomy surgery. This trial compares the effects of hydrocortisone to a placebo in patients undergoing this procedure.

Pancreatic Resection>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Nephrotic Syndrome: Ketoanalogues for Muscle Preservation

We are studying a new treatment to help prevent muscle loss in patients with nephrotic syndrome. This trial will assess its safety and how it may improve overall health and quality of life.

Protein-Energy Wasting in Nephrotic Syndrome>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Infant Immunity to Whooping Cough: Maternal Vaccination Study

We are studying how vaccines given to pregnant women affect their infants' immunity to whooping cough. Our goal is to find out what factors influence the transfer of protective antibodies from mothers to their babies.

Whooping Cough>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementGynecology and ObstetricsInfectious DiseasesInternal Medicine

Rheumatoid Arthritis: F8IL10 Injection Study

We are exploring different doses of an injection for people with rheumatoid arthritis. The goal is to find out how well it works and its safety profile.

Rheumatoid Arthritis>2 yearsSafety phase (I)Rheumatology

Midgut Neuroendocrine Tumors: Lu177-Dotatate Treatment Schedule

We are studying whether giving Lu177-Dotatate every 16 weeks can lower serious side effects for patients with advanced midgut neuroendocrine tumors. This trial compares the new schedule to the standard treatment given every 8 weeks.

Small Intestine Neuroendocrine Tumor>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyOncology

Small Cell Lung Cancer: MK-6070 and Ifinatamab Deruxtecan Study

We are studying the safety and effectiveness of MK-6070 combined with ifinatamab deruxtecan in people with advanced small cell lung cancer. This trial aims to find better treatment options for those whose cancer has returned or is hard to treat.

Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Septic Shock: Comparing Sodium Lactate and Saline Solutions

We are studying how two different intravenous fluids affect blood flow and acid-base balance in patients with septic shock. This research may help improve treatment options for this serious condition.

Septic Shock>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicinePulmonology

Blood Cancer Treatment: SMART101 After Stem Cell Transplant

We are studying the safety and effectiveness of SMART101 for patients with blood cancers after stem cell transplantation. The goal is to see if it helps improve immune recovery and reduce complications.

Allogenic Stem Cell Transplantation>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyInfectious Diseases

Leukemia Treatment: Ponatinib vs. Imatinib

We are studying whether ponatinib combined with chemotherapy is as effective as imatinib for adults with Philadelphia-Chromosome positive acute lymphoblastic leukemia. The trial also evaluates treatment outcomes for patients who respond differently.

Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Non-Small Cell Lung Cancer: Sigvotatug Vedotin with Pembrolizumab

We are studying a new treatment combining sigvotatug vedotin with pembrolizumab for patients with advanced non-small cell lung cancer that has high PD-L1 levels. The goal is to see if this combination works better than pembrolizumab alone.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Cardiac Amyloidosis: PET Imaging with Vizamyl®

We are studying a new imaging tracer to see how effectively it detects amyloid deposits in the hearts of patients with cardiac amyloidosis. This research may help improve diagnosis and understanding of the disease.

Cardiac Amyloidosis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiology

Oxytocin and Trust Learning in Attachment Development

We are exploring how oxytocin may influence trust learning and cognitive flexibility in a virtual reality setting. This study aims to understand its effects on social bonding and learning processes.

Healthy Children>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsStandard MedicinesPsychiatry

Hepatocellular Cancer and Lung Cancer: ABBV-324 vs. Lenvatinib

We are comparing an intravenous treatment to an oral medication for adults with hepatocellular cancer or squamous-cell lung cancer. The study aims to assess side effects and changes in disease activity.

Liver CancerNon-Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Septic Shock: Mesenchymal Stem Cells Treatment

We are studying whether early administration of mesenchymal stem cells can improve organ function in patients with septic shock. This trial compares the effects of MSCs to standard treatment in intensive care.

Severe Septic Shock>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyInfectious DiseasesInternal MedicinePulmonology

DMT: Study in Healthy Volunteers

We are investigating the effects of DMT in healthy individuals to understand its safety and potential benefits. This research may help us learn more about how DMT works in the body.

Stroke>2 yearsSafety phase (I)Neurology

Small Cell Lung Cancer: 177Lu-EVG321 Treatment

We are testing a new drug to see if it is safe and how well the body tolerates it in patients with small cell lung cancer. This study aims to gather important information for future treatments.

Small Cell Lung Cancer>2 yearsSafety phase (I)OncologyPulmonology

Opioid-Induced Respiratory Depression: Naloxone and Nalmefene Study

We are studying how well naloxone and nalmefene can reverse breathing problems caused by opioids in both new and long-term users. This research aims to improve treatment options for respiratory depression in real-life settings.

Healthy VolunteersOpioid Use Disorder>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal MedicineOtolaryngologyPulmonology

Orthopedic Surgery: Intraoperative Methadone Study

We are investigating whether methadone can reduce pain and improve satisfaction after orthopedic surgery compared to standard pain relief methods. This study aims to ensure safety while managing postoperative pain effectively.

Orthopedic Surgery>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOrthopedics and Traumatology

Advanced Solid Tumors: INP12 Treatment

We are evaluating the safety and how the body handles a new treatment called INP12 in patients with advanced solid tumors. This study aims to understand if INP12 is safe for further testing.

Solid Tumor>2 yearsSafety phase (I)Oncology